Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021.
 Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424.
 Fagin J A and Wells S A. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med, 2016. 375(23): p. 2307.
 Seib C D and Sosa J A. Evolving Understanding of the Epidemiology of Thyroid Cancer. Endocrinol Metab Clin North Am, 2019. 48(1): p. 23-35.
 Zeng R, Zhao M, Niu H, et al. Relationship between Hashimoto's thyroiditis and papillary thyroid carcinoma in children and adolescents. Eur Rev Med Pharmacol Sci, 2018. 22(22): p. 7778-7787.
 Basak E A, van der Meer J W M, Hurkmans D P, et al. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. Thyroid, 2020. 30(7): p. 966-973.
 Kim H I, Kim K, Park S Y, et al. Refining the eighth edition AJCC TNM classification and prognostic groups for papillary thyroid cancer with lateral nodal metastasis. Oral Oncol, 2018. 78: p. 80-86.
 Joyce J A and Fearon D T. T cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015. 348(6230): p. 74-80.
 Ferrari S M, Fallahi P, Galdiero M R, et al. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int J Mol Sci, 2019. 20(18).
 Chen D S and Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity, 2013. 39(1): p. 1-10.
 Lu H, Zhang L, Dai Y, et al. Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma. Diagn Pathol, 2020. 15(1): p. 16.
 Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol, 1996. 8(5): p. 765-72.
 Keir M E, Butte M J, Freeman G J, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008. 26: p. 677-704.
 Thommen D S and Schumacher T N. T Cell Dysfunction in Cancer. Cancer Cell, 2018. 33(4): p. 547-562.
 Tumeh P C, Harview C L, Yearley J H, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 2014. 515(7528): p. 568-71.
 Ohaegbulam K C, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med, 2015. 21(1): p. 24-33.
 Cha J H, Chan L C, Li C W, et al. Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell, 2019. 76(3): p. 359-370.
 Fife B T and Bluestone J A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev, 2008. 224: p. 166-82.
 Salama A D, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med, 2003. 198(1): p. 71-8.
 Kato T, Noma K, Ohara T, et al. Cancer-Associated Fibroblasts Affect Intratumoral CD8(+) and FoxP3(+) T Cells Via IL6 in the Tumor Microenvironment. Clin Cancer Res, 2018. 24(19): p. 4820-4833.
 Fiore E, Rago T, Latrofa F, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer, 2011. 18(4): p. 429-37.
 Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol, 2015. 7(3): p. 327-43.
 Li W, Ming H, Sun D, et al. The relationship between BRAFV600E, NF-kappaB and TgAb expression in papillary thyroid carcinoma. Pathol Res Pract, 2017. 213(3): p. 183-188.